DPP-4 is overexpressed in lung tissue from idiopathic pulmonary patients and activates lung fibroblasts

  1. Paula Montero Magalló 1
  2. Javier Milara 24
  3. Inés Roger 1
  4. Cristina Estornut 11
  5. Julio Cortijo 23
  1. 1 Universitat de València
    info

    Universitat de València

    Valencia, España

    ROR https://ror.org/043nxc105

  2. 2 Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias
    info

    Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias

    Madrid, España

  3. 3 Hospital General Universitario de Valencia
    info

    Hospital General Universitario de Valencia

    Valencia, España

    ROR https://ror.org/03sz8rb35

  4. 4 Pharmacy Department, General Hospital of Valencia
Konferenzberichte:
European Respiratory Journal

Verlag: European Respiratory Society

ISSN: 0903-1936 1399-3003

Datum der Publikation: 2020

Ausgabe: 56

Nummer: suppl 64

Art: Konferenz-Beitrag

DOI: 10.1183/13993003.CONGRESS-2020.3375 GOOGLE SCHOLAR lock_openOpen Access editor

Zusammenfassung

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible form of fibrotic interstitial lung disease, characterized by uncontrolled fibroblast invasion. Dipeptidyl peptidase-4 (DPP-4)/ glucagon-like peptide 1 (GLP-1) system is involved in multiple effects, including cardiac, liver or kidney fibrosis. However, its implication in IPF has not been described.Objective: To analyse the implication of DPP4/GLP1 system in IPF.Methods: Protein expression of DPP4, GLP-1 and GLP-1 receptor was analyzed in lung tissues from 7 IPF patients. TGFβ1-induced fibroblast to myofibroblast transition (FMT), epithelial to mesenchymal transition (EMT) and mesothelial to mesenchymal transition (MMT) were evaluated in vitro in lung MRC5 and primary IPF lung fibroblasts, alveolar type II A549, and mesothelial Met5A cells. Antifibrotic effects of sitagliptin, an inhibitor of DPP-4, and liraglutide, a GLP-1 analogue, were evaluated.Results: DPP-4 and GLP-1 protein expression were increased in lung tissue of IPF patients vs healthy subjects, while GLP-1 receptor protein expression was decreased in IPF lung tissue. TGFβ1 promoted FMT by increasing a-SMA, Col-I, CTGF, FN-1 and IL-13 in MRC5 and IPF primary lung fibroblasts. Sitagliptin but not liraglutide, was able to reduce myofibroblast markers. Neither sitagliptin nor liraglutide inhibited the EMT and MMT processes in A549 and Met5A cells.Conclusions: DPP-4 and GLP-1 are increased in IPF patients while GLP1-receptor is decreased. Sitagliptin but not liraglutide reduced the TGFb1-induced FMT in both MRC5 and primary IPF lung fibroblasts. Pharmacological inhibition of DPP-4 may be a promising target for the treatment of IPF.Footnotes Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3375.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at [www.ers-education.org][1] (ERS member access only). [1]: http://www.ers-education.org